Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT00764595 Completed - Metastatic Cancer Clinical Trials

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

GISTs
Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and to see how well it works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

NCT ID: NCT00762346 Completed - Clinical trials for Non Small Cell Lung Cancer

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Start date: September 2008
Phase: Phase 4
Study type: Interventional

A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.

NCT ID: NCT00757757 Terminated - Prostate Cancer Clinical Trials

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

NCT ID: NCT00754442 Completed - Clinical trials for Secondary Hyperparathyroidism

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

1hydroxylase
Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

NCT ID: NCT00752570 Completed - Cancer Clinical Trials

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.

NCT ID: NCT00748631 Terminated - Multiple Myeloma Clinical Trials

Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.

KYPHOK
Start date: October 2007
Phase: N/A
Study type: Interventional

Balloon Kyphoplasty is an alternative to vertebroplasty in the treatment of painful malignant vertebral fractures. This is a mini-invasive percutaneous treatment, aiming to stabilize the vertebral fracture, decrease of pain. This technique also improves patient function. Namely, bedridden patients are often able to resume walking in the days following vertebral cement injection. Advantage of Balloon Kyphoplasty as compared to vertebroplasty is the ability to inject the cement into the diseased vertebral body which shows cortical destruction with lower pressure, thereby possibly reducing cement leakage and related complications. This is a multicentric, observational prospective study. Patients are evaluated before and after the procedure. Sixty women or men older than 18 years, with 1 to 3 painful vertebral fracture(s) of malignant origin (due to multiple myeloma or osteolytic vertebral metastasis) will be enrolled. Each patient will be followed during 1 year after the procedure with 7 visits at D-8, D-1, D1, D15, D90, D180, and D360 or until the death of the patient. The main evaluation outcome is patient self-global satisfaction regarding the procedure on a semi-quantitative satisfaction scale, 15 days after the Balloon Kyphoplasty.

NCT ID: NCT00748046 Completed - Prostate Cancer Clinical Trials

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).

NCT ID: NCT00745797 Terminated - Brain Metastases Clinical Trials

Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy

PCI
Start date: April 2008
Phase: Phase 3
Study type: Interventional

1. Patients with confirmed advanced NSCLC and any response to 3-6 cycles of chemotherapy, were randomized to receive PCI (30 Gy/10fr) or no PCI. 2. The primary endpoint was the cumulative incidence of symptomatic brain metastases (BM) . 3. The study was sized to detect a hazard ratio of 0.37 with 80% power and 2-sided 5% significance (60 events, 206 patients).

NCT ID: NCT00743678 Completed - Colorectal Cancer Clinical Trials

Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis

Start date: June 2008
Phase: Phase 2
Study type: Interventional

An innovative therapeutic strategy to increase the complete resection rate is of utmost importance in order to enhance survival in colorectal cancer patients with unresectable liver-only metastasis. Therefore, the investigators propose a prospective study of neoadjuvant chemotherapy using FOLFOX6 plus cetuximab to convert initially unresectable liver metastasis to potentially resectable disease.

NCT ID: NCT00742716 Completed - Clinical trials for Chronic Kidney Disease

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK) in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis. This study will also investigate the safety and effects of different strengths of CTA018, on parathyroid hormone (PTH) levels.